**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 72008

**Manuscript Type:** LETTER TO THE EDITOR

**Novel appearance of hyperglycemia/diabetes, associated with COVID-19**

Ilias I. New-onset diabetes in COVID-19

Ioannis Ilias

**Ioannis Ilias,** Department of Endocrinology, Diabetes & Metabolism, Elena Venizelou Hospital, Athens GR-11521, Greece

**Author contributions:** Ilias Ι conceived and wrote this letter.

**Corresponding author: Ioannis Ilias, MD, PhD, Consultant Physician-Scientist,** Department of Endocrinology, Diabetes & Metabolism, Elena Venizelou Hospital, 2 Elena Venizelou Sq., Athens GR-11521, Greece. iiliasmd@yahoo.com

**Received:** September 29, 2021

**Revised:** January 12, 2022

**Accepted: March 15, 2022**

**Published online:**

**Abstract**

In a recent meta-analysis the prevalence of coronavirus disease 2019 (COVID-19)-associated hyperglycemia was 25%, and that of COVID-19-associated new-onset diabetes was 19%. An association between hyperglycemia or new-onset diabetes and COVID-19 has been suggested. In a recent relevant study of critically and non-critically ill patients with COVID-19, we found that indeed beta-cell function was compromised in critically ill patients with COVID-19 and that these patients showed a high glycemic gap. Nevertheless, one quarter of critically ill patients with no history of diabetes have stress hyperglycemia, a finding which could obscure the prevalence of hyperglycemia or new-onset diabetes that could be attributed to COVID-19 *per se*.

**Key Words:** Blood glucose; Pandemics; Severe acute respiratory syndrome coronavirus 2; Humans; Hyperglycemia; Hospitalization

Ilias I. Novel appearance of hyperglycemia/diabetes, associated with COVID-19. *World J Virol* 2022; In press

**Core Tip:** An association between hyperglycemia or new-onset diabetes and coronavirus disease 2019 (COVID-19) has been suggested. Nevertheless, one quarter of critically ill patients with no history of diabetes have stress hyperglycemia, a finding which could obscure the prevalence of hyperglycemia or new-onset diabetes that could be attributed to COVID-19 *per se*.

**TO THE EDITOR**

We have read with great interest the work by Shrestha *et al*[1] regarding new-onset hyperglycemia/diabetes (DM) in patients with coronavirus disease 2019 (COVID-19). With an erudite meta-analysis the authors found that the pooled prevalence of COVID-19-associated hyperglycemia was 25.23% and that the prevalence of COVID-19-associated new-onset DM was 19.70%[1].

An association between hyperglycemia/new-onset DM and COVID-19 has been suggested[2], *via* decreased insulin secretion and increased insulin resistance[2,3]. In a recent relevant study, of critically and non-critically ill patients with COVID-19, we found that indeed beta cell function (based on glucose and insulin measurements and using the Homeostasis Model Assessment HOMA2 estimate of steady state beta cell function[4]) was compromised in critically ill patients with COVID-19. Furthermore, these patients showed a high glycemic gap (based on admission glucose and glycated hemoglobin measurements)[5]. Nevertheless, we acknowledged that on average, 25% of critically ill patients with no history of DM have stress hyperglycemia[5-7], a finding which could obscure the prevalence of hyperglycemia/new-onset DM that could be attributed to COVID-19 *per se*.

Thus, it would be interesting if the results of the study by Shrestha *et al*[1] were presented separately-if possible-for critically and non-critically ill patients with COVID-19 and compared to non-COVID-19 patients.

**REFERENCES**

1 **Shrestha DB**, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, Rabaan AA, Karki BJ. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. *World J Virol* 2021; **10**: 275-287 [PMID: 34631477 DOI: 10.5501/wjv.v10.i5.275]

2 **Muniangi-Muhitu H**, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA. Covid-19 and Diabetes: A Complex Bidirectional Relationship. *Front Endocrinol (Lausanne)* 2020; **11**: 582936 [PMID: 33133024 DOI: 10.3389/fendo.2020.582936]

3 **Lim S**, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol* 2021; **17**: 11-30 [PMID: 33188364 DOI: 10.1038/s41574-020-00435-4]

4 **Wallace TM**, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004; **27**: 1487-1495 [PMID: 15161807 DOI: 10.2337/diacare.27.6.1487]

5 **Ilias I**, Diamantopoulos A, Pratikaki M, Botoula E, Jahaj E, Athanasiou N, Tsipilis S, Zacharis A, Vassiliou AG, Vassiliadi DA, Kotanidou A, Tsagarakis S, Dimopoulou I. Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients. *Medicina (Kaunas)* 2021; **57** [PMID: 33466617 DOI: 10.3390/medicina57010068]

6 **Bellaver P**, Schaeffer AF, Dullius DP, Viana MV, Leitão CB, Rech TH. Association of multiple glycemic parameters at intensive care unit admission with mortality and clinical outcomes in critically ill patients. *Sci Rep* 2019; **9**: 18498 [PMID: 31811218 DOI: 10.1038/s41598-019-55080-3]

7 **Ali Abdelhamid Y**, Kar P, Finnis ME, Phillips LK, Plummer MP, Shaw JE, Horowitz M, Deane AM. Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and meta-analysis. *Crit Care* 2016; **20**: 301 [PMID: 27677709 DOI: 10.1186/s13054-016-1471-6]

**Footnotes**

**Conflict-of-interest statement:** The author declares no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 29, 2021

**First decision:** January 12, 2022

**Article in press:**

**Specialty type:** Virology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Gonzalez FM, Chile; Gupta S, United States; Wang TJ, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR